Press Release Details

View all news

Arcus Biosciences to Participate in the 2018 Wedbush PacGrow Healthcare Conference

August 01, 2018

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Terry Rosen, Ph.D., Chief Executive Officer, will participate in a fireside chat at the 2018 Wedbush PacGrow Healthcare Conferenceon Tuesday, August 14, 2018at 2:30 pm ET at the Parker New York, in New York City, NY.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist AB928, which is being evaluated in combination with other agents in multiple tumor types in a Phase 1/1b program, and an anti-PD-1 antibody AB122, which is being evaluated in a Phase 1 trial and will be tested in combination with Arcus’s other product candidates. Arcus’s other programs include an anti-TIGIT antibody AB154, which is in a phase 1 program, and a small molecule inhibitor of CD73 AB680, which is in IND-enabling studies. Arcus has extensive in-house expertise in medicinal chemistry, immunology, biochemistry, pharmacology and structural biology. For more information about Arcus Biosciences, please visit www.arcusbio.com.

Arcus Biosciences
Jennifer Jarrett, 510-694-6261
jjarrett@arcusbio.com
or
Nicole Arndt, 510-284-4728
narndt@arcusbio.com

Source: Arcus Biosciences

Categories: Press Releases
View all news